Published in J Eur Acad Dermatol Venereol on July 01, 2001
Cost-of-illness in psoriasis: comparing inpatient and outpatient therapy. PLoS One (2013) 0.77
The cost of hospital-related care of patients with psoriasis in Italy based on the AISP study. Associazione Italiana Studi Psoriasi. J Eur Acad Dermatol Venereol (2001) 2.27
The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol (2001) 3.92
Sterility of refrigerated injectable collagen syringes after injection of patient. J Am Acad Dermatol (1992) 2.05
Finasteride in the treatment of men with frontal male pattern hair loss. J Am Acad Dermatol (1999) 1.67
Duration of remission of psoriasis therapies. J Am Acad Dermatol (1999) 1.51
Pustular and erythrodermic psoriasis complicated by acute respiratory distress syndrome. Arch Dermatol (1997) 1.48
Proceedings of the Psoriasis Combination and Rotation Therapy Conference. Deer Valley, Utah, Oct. 7-9, 1994. J Am Acad Dermatol (1996) 1.45
New cutaneous manifestations of systemic diseases. Am Fam Physician (1995) 1.42
Effect of UV-B phototherapy on plasma HIV type 1 RNA viral level: a self-controlled prospective study. Arch Dermatol (1998) 1.40
A 500-kb region on chromosome 16p13.1 contains the pseudoxanthoma elasticum locus: high-resolution mapping and genomic structure. J Mol Med (Berl) (2000) 1.39
Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol (1998) 1.39
Respiratory symptoms and lung function in garage workers and taxi drivers. J R Soc Promot Health (1998) 1.38
Atopic dermatitis. Lancet (1998) 1.37
Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol (2013) 1.26
Cellular differentiation and expression of matrix genes in type 1 neurofibromatosis. Lab Invest (1988) 1.19
Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol (2000) 1.12
Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J Am Acad Dermatol (2000) 1.11
Metastatic Crohn's disease. J Am Acad Dermatol (1984) 1.07
Diagnosis of pseudoxanthoma elasticum by scar biopsy in patients without characteristic skin lesions. N Engl J Med (1987) 1.07
Induction of 8-oxo-7,8-dihydro-2'-deoxyguanosine by ultraviolet radiation in calf thymus DNA and HeLa cells. Photochem Photobiol (1997) 1.06
Pseudoxanthoma elasticum: significance of limited phenotypic expression in parents of affected offspring. J Am Acad Dermatol (2001) 1.05
Altered expression of angiopoietins and Tie2 endothelium receptor in psoriasis. J Invest Dermatol (2001) 1.05
Identification of possible reactive oxygen species involved in ultraviolet radiation-induced oxidative DNA damage. Free Radic Biol Med (1997) 1.00
Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. Br J Dermatol (2011) 1.00
Benzo[a]pyrene enhances the formation of 8-hydroxy-2'-deoxyguanosine by ultraviolet A radiation in calf thymus DNA and human epidermoid carcinoma cells. Biochemistry (1998) 0.98
Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled study. J Am Acad Dermatol (2000) 0.97
Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic. J Eur Acad Dermatol Venereol (2010) 0.97
DNA structural integrity and base composition affect ultraviolet light-induced oxidative DNA damage. Biochemistry (1998) 0.96
Scavenging of hydrogen peroxide and inhibition of ultraviolet light-induced oxidative DNA damage by aqueous extracts from green and black teas. Free Radic Biol Med (1999) 0.95
Collagen alterations in chronically sun-damaged human skin. Photochem Photobiol (1993) 0.95
Calcification of elastic fibers in pseudoxanthoma elasticum. Mt Sinai J Med (1996) 0.93
Subcutaneous fat necrosis of the newborn with hypercalcemia. J Am Acad Dermatol (1987) 0.91
Isoflavone genistein inhibits the initiation and promotion of two-stage skin carcinogenesis in mice. Carcinogenesis (1998) 0.90
Elastin gene deletions in Williams syndrome patients result in altered deposition of elastic fibers in skin and a subclinical dermal phenotype. Pediatr Dermatol (2000) 0.90
Ultraviolet radiation increases tropoelastin accumulation by a post-transcriptional mechanism in dermal fibroblasts. J Invest Dermatol (1995) 0.90
Nerve growth factor receptors on dissociated neurofibroma Schwann-like cells. Cancer Res (1986) 0.89
Hypopigmented variant of mycosis fungoides: demography, histopathology, and treatment of seven cases. J Am Acad Dermatol (1995) 0.89
Inhibition of ultraviolet B (UVB)-induced c-fos and c-jun expression in vivo by a tyrosine kinase inhibitor genistein. Carcinogenesis (1998) 0.89
Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. J Am Acad Dermatol (1997) 0.89
Cutaneous mycobacteriosis: occurrence and significance in two patients with the acquired immunodeficiency syndrome. Arch Dermatol (1987) 0.89
Basement membrane proteins, interstitial collagens, and fibronectin in neurofibroma. J Invest Dermatol (1985) 0.88
Differential regulation of P53 and Bcl-2 expression by ultraviolet A and B. J Invest Dermatol (1998) 0.86
Kaposi's sarcoma and acquired immunodeficiency syndrome. Postmortem findings in twenty-four cases. J Am Acad Dermatol (1987) 0.84
Acanthosis Nigricans, insulin action, and hyperandrogenism: clinical, histological, and biochemical findings. J Clin Endocrinol Metab (1991) 0.84
Consensus workshop on the toxic effects of long-term PUVA therapy. Arch Dermatol (1998) 0.84
Tamoxifen reduces endogenous and UV light-induced oxidative damage to DNA, lipid and protein in vitro and in vivo. Carcinogenesis (1998) 0.83
Combination therapy with vitamin D analogues. Br J Dermatol (2001) 0.83
The efficacy of metronidazole 1% cream once daily compared with metronidazole 1% cream twice daily and their vehicles in rosacea: a double-blind clinical trial. J Am Acad Dermatol (1998) 0.81
Peristomal pyoderma gangrenosum. J Am Acad Dermatol (1992) 0.81
Pseudoxanthoma elasticum and calcinosis cutis. J Am Acad Dermatol (2000) 0.81
Topical corticosteroids in psoriasis: strategies for improving safety. J Eur Acad Dermatol Venereol (2009) 0.81
Acne therapy: clinical pearls. Semin Cutan Med Surg (2001) 0.80
Pets, allergy and respiratory symptoms in children living in a desert country. Allerg Immunol (Paris) (1995) 0.80
Multiple hamartoma syndrome. J Am Acad Dermatol (1987) 0.80
Treatment of verrucae vulgaris with alpha 2 interferon. J Infect Dis (1986) 0.80
Pemphigus vulgaris after initiation of psoralen and UVA therapy for psoriasis. J Am Acad Dermatol (1994) 0.80
Photoinduced dermal pigmentation in patients taking tricyclic antidepressants: histology, electron microscopy, and energy dispersive spectroscopy. J Am Acad Dermatol (1999) 0.80
The use of alefacept in the treatment of psoriasis. Skin Therapy Lett (2003) 0.80
Physician perceptions and experience of current treatment in actinic keratosis. J Eur Acad Dermatol Venereol (2014) 0.80
Association between acrochordons and colonic polyps. J Am Acad Dermatol (1986) 0.79
Association of Pityrosporum orbiculare (Malassezia furfur) with seborrheic dermatitis in patients with acquired immunodeficiency syndrome (AIDS). J Am Acad Dermatol (1989) 0.79
PUVA (8-methoxy-psoralen plus ultraviolet A) induces the formation of 8-hydroxy-2'-deoxyguanosine and DNA fragmentation in calf thymus DNA and human epidermoid carcinoma cells. Free Radic Biol Med (1999) 0.79
Compatibility of calcipotriene with other topical medications. J Am Acad Dermatol (1998) 0.79
Factors impacting the combination of topical corticosteroid therapies for psoriasis: perspectives from the International Psoriasis Council. J Eur Acad Dermatol Venereol (2011) 0.79
Alefacept in the treatment of psoriasis in patients for whom conventional therapies are inadequate. Dermatology (2005) 0.79
Determination of desmosines in elastin-related skin disorders by isocratic high-performance liquid chromatography. Exp Mol Pathol (1990) 0.79
Cutaneous reactions to vitamin K1 injections. J Am Acad Dermatol (1993) 0.79
Presence of type I and VI collagen mRNAs in endothelial cells in cutaneous neurofibromas. Lab Invest (1991) 0.79
Acquired ichthyosis and hyperparathyroidism. J Am Acad Dermatol (1989) 0.79
Serologic tests for treponematoses in the United Arab Emirates. Int J Dermatol (1996) 0.78
Elastase digestion of normal and pseudoxanthoma elasticum lesional skin elastins. Exp Mol Pathol (1991) 0.78
Tinea versicolor treated with terbinafine 1% solution. Int J Dermatol (1999) 0.78
Cutaneous manifestations of inflammatory bowel disease. J Eur Acad Dermatol Venereol (2000) 0.78
Abnormalities of fibrillin in acquired cutis laxa. J Am Acad Dermatol (1994) 0.78
Interactions between tazarotene and ultraviolet light. J Am Acad Dermatol (1999) 0.77
Pattern of cancer in the United Arab Emirates referred to Al-Ain Hospital. Ann Saudi Med (1997) 0.77
Topical calcipotriene in combination with UVB phototherapy for psoriasis. Int J Dermatol (1997) 0.77
A double-blind, vehicle-controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis. J Am Acad Dermatol (1991) 0.77
Psoriasis. Drugs Today (Barc) (1998) 0.76
Psoriasis and Crohn's disease. Mt Sinai J Med (1999) 0.76
Retrospective study of the efficacy of narrowband UVB and acitretin. J Dermatolog Treat (2003) 0.76
From the literature: intralesional 5-FU in the treatment of hypertrophic scars and keloids: clinical experience. J Am Acad Dermatol (2000) 0.76
In vitro compatibility of tazarotene with other topical treatments of psoriasis. J Am Acad Dermatol (2000) 0.76
Cost-effectiveness of methotrexate and Goeckerman therapy: a flawed analysis. Arch Dermatol (1999) 0.75
Retrospective analysis of the treatment of psoriasis of the palms and soles. J Dermatolog Treat (2003) 0.75
Improving the safety profile of long-term PUVA therapy. J Am Acad Dermatol (1999) 0.75
Addition of short-contact anthralin therapy to an ultraviolet B phototherapy regimen: assessment of efficacy. J Am Acad Dermatol (1985) 0.75
Immunofluorescence and electron microscopic findings in a congenital arrector pili hamartoma. Am J Dermatopathol (1989) 0.75
Generalized morphea. Mt Sinai J Med (1998) 0.75
Erythema nodosum. Mt Sinai J Med (1999) 0.75
Coexistence of atopic dermatitis and lichen nitidus in three patients. Dermatology (1996) 0.75
The penetration of 0.005% fluticasone propionate ointment in eyelid skin. J Am Acad Dermatol (2001) 0.75
Case 2-1995. From the weekly grand rounds of the Department of Dermatology at the Mount Sinai Hospital. Mt Sinai J Med (1995) 0.75
Topical antipsoriatics. Skin Therapy Lett (2000) 0.75
Comparison of urinary 8-hydroxy-2'-deoxyguanosine in patients treated with topical corticosteroids, UV-B, and psoralen UV-A therapies. Arch Dermatol (2000) 0.75
Cimetidine therapy for plantar warts. J Am Podiatr Med Assoc (1995) 0.75
Henoch-Schönlein purpura. Case report and review of the literature. J Am Podiatr Med Assoc (1995) 0.75
Extramammary Paget's disease. Mt Sinai J Med (2000) 0.75
The case for micrographically controlled skin surgery. J Am Acad Dermatol (2000) 0.75
Serum IgE level and clinical allergic diseases in the United Arab Emirates. Allerg Immunol (Paris) (1997) 0.75
Lyme disease. Mt Sinai J Med (1997) 0.75